Ultra-high yield of alpha-1-anti-trypsin
AssigneePlasma Technologies, LLC
InventorsGene Zurlo, Dennis Curtin, Allan Louderback
Life of this patent
Estimating the term…
Abstract
The instant invention provides novel and effective methods of isolating alpha-1-antitrypsin from cryo-poor plasma and formulating it into therapeutic products. This invention achieves higher yields and a superior quality of alpha-1-antitrypsin. Alpha-1-antitrypsin is isolated from cryo-poor plasma, using one or more salts selected from a group comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two fractionation steps, followed by diafiltration to remove those salts employed.
Claims14
A method of extracting alpha-1-antitrypsin from plasma, comprising:
- providing a non-salted, non-precipitated, previously frozen blood product;
- salting the previously frozen blood product to produce a first intermediate having a total salt content of between 11-13% wt;
- centrifuging the first intermediate to produce a first supernatant and a first paste;
- salting the first supernatant to produce a second intermediate with a total salt content of between at least 21-23% wt;
- centrifuging the second intermediate to produce a second supernatant and a second paste;
- rehydrating the first paste, de-salting the first paste and the second supernatant, and passing the de-salted first paste and second supernatant through at least one of an ion exchange column or an affinity column to produce a first and second alpha-1-antitrypsin effluent;
- and
- combining the first and second effluents to produce a product containing the alpha-1-antitrypsin.
Dependencies are inferred from the claim text.